Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy

Ianko D. Iankov, Boris Blechacz, Chunsheng Liu, Jeffrey D. Schmeckpeper, James E. Tarara, Mark J Federspiel, Noel Caplice, Stephen J Russell

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Attenuated measles viruses (MVs) propagate selectively in human tumor cells, and phase I clinical trials are currently underway to test their oncolytic activity. A major theoretical impediment to systemic MV application is the presence of pre-existing antiviral immunity. We hypothesized that autologous MV-infected cells might be a more reliable vehicle than cell-free virions to deliver the infection to tumor cells in subjects with neutralizing titers of anti-measles antibodies. Our in vitro studies, using a dual-color fluorescent model, demonstrated efficient cell-to-cell transfer of infection via heterofusion. In contrast to infection by naked virions, heterofusion between infected cell carriers and tumor cells was more resistant to antibody neutralization. Infected monocytic, endothelial, or stimulated peripheral blood cells could deliver oncolytic MV to tumor lesions in vivo, after intravenous (i.v.) or intraperitoneal (i.p.) administration. Single or repeated i.p. injections of monocytic carriers significantly improved survival of animals bearing human ovarian cancer xenografts. Systemic or i.p. injection of MV-infected cells successfully transferred infection by heterofusion to Raji lymphomas or hepatocellular carcinoma tumors in the presence of neutralizing antibodies. These results suggest a novel strategy for systemic delivery of oncolytic virotherapy in cancer patients that can "bypass" the pre-existing humoral immunity against MV.

Original languageEnglish (US)
Pages (from-to)114-122
Number of pages9
JournalMolecular Therapy
Volume15
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Oncolytic Viruses
Measles virus
Neoplasms
Infection
Intraperitoneal Injections
Virion
Oncolytic Virotherapy
Clinical Trials, Phase I
Measles
Humoral Immunity
Neutralizing Antibodies
Heterografts
Ovarian Neoplasms
Antiviral Agents
Anti-Idiotypic Antibodies
Hepatocellular Carcinoma
Immunity
Lymphoma
Blood Cells
Color

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Infected cell carriers : A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. / Iankov, Ianko D.; Blechacz, Boris; Liu, Chunsheng; Schmeckpeper, Jeffrey D.; Tarara, James E.; Federspiel, Mark J; Caplice, Noel; Russell, Stephen J.

In: Molecular Therapy, Vol. 15, No. 1, 01.2007, p. 114-122.

Research output: Contribution to journalArticle

Iankov, Ianko D. ; Blechacz, Boris ; Liu, Chunsheng ; Schmeckpeper, Jeffrey D. ; Tarara, James E. ; Federspiel, Mark J ; Caplice, Noel ; Russell, Stephen J. / Infected cell carriers : A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. In: Molecular Therapy. 2007 ; Vol. 15, No. 1. pp. 114-122.
@article{32553f8c51de4d788b42a00ca0f058a1,
title = "Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy",
abstract = "Attenuated measles viruses (MVs) propagate selectively in human tumor cells, and phase I clinical trials are currently underway to test their oncolytic activity. A major theoretical impediment to systemic MV application is the presence of pre-existing antiviral immunity. We hypothesized that autologous MV-infected cells might be a more reliable vehicle than cell-free virions to deliver the infection to tumor cells in subjects with neutralizing titers of anti-measles antibodies. Our in vitro studies, using a dual-color fluorescent model, demonstrated efficient cell-to-cell transfer of infection via heterofusion. In contrast to infection by naked virions, heterofusion between infected cell carriers and tumor cells was more resistant to antibody neutralization. Infected monocytic, endothelial, or stimulated peripheral blood cells could deliver oncolytic MV to tumor lesions in vivo, after intravenous (i.v.) or intraperitoneal (i.p.) administration. Single or repeated i.p. injections of monocytic carriers significantly improved survival of animals bearing human ovarian cancer xenografts. Systemic or i.p. injection of MV-infected cells successfully transferred infection by heterofusion to Raji lymphomas or hepatocellular carcinoma tumors in the presence of neutralizing antibodies. These results suggest a novel strategy for systemic delivery of oncolytic virotherapy in cancer patients that can {"}bypass{"} the pre-existing humoral immunity against MV.",
author = "Iankov, {Ianko D.} and Boris Blechacz and Chunsheng Liu and Schmeckpeper, {Jeffrey D.} and Tarara, {James E.} and Federspiel, {Mark J} and Noel Caplice and Russell, {Stephen J}",
year = "2007",
month = "1",
doi = "10.1038/sj.mt.6300020",
language = "English (US)",
volume = "15",
pages = "114--122",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Infected cell carriers

T2 - A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy

AU - Iankov, Ianko D.

AU - Blechacz, Boris

AU - Liu, Chunsheng

AU - Schmeckpeper, Jeffrey D.

AU - Tarara, James E.

AU - Federspiel, Mark J

AU - Caplice, Noel

AU - Russell, Stephen J

PY - 2007/1

Y1 - 2007/1

N2 - Attenuated measles viruses (MVs) propagate selectively in human tumor cells, and phase I clinical trials are currently underway to test their oncolytic activity. A major theoretical impediment to systemic MV application is the presence of pre-existing antiviral immunity. We hypothesized that autologous MV-infected cells might be a more reliable vehicle than cell-free virions to deliver the infection to tumor cells in subjects with neutralizing titers of anti-measles antibodies. Our in vitro studies, using a dual-color fluorescent model, demonstrated efficient cell-to-cell transfer of infection via heterofusion. In contrast to infection by naked virions, heterofusion between infected cell carriers and tumor cells was more resistant to antibody neutralization. Infected monocytic, endothelial, or stimulated peripheral blood cells could deliver oncolytic MV to tumor lesions in vivo, after intravenous (i.v.) or intraperitoneal (i.p.) administration. Single or repeated i.p. injections of monocytic carriers significantly improved survival of animals bearing human ovarian cancer xenografts. Systemic or i.p. injection of MV-infected cells successfully transferred infection by heterofusion to Raji lymphomas or hepatocellular carcinoma tumors in the presence of neutralizing antibodies. These results suggest a novel strategy for systemic delivery of oncolytic virotherapy in cancer patients that can "bypass" the pre-existing humoral immunity against MV.

AB - Attenuated measles viruses (MVs) propagate selectively in human tumor cells, and phase I clinical trials are currently underway to test their oncolytic activity. A major theoretical impediment to systemic MV application is the presence of pre-existing antiviral immunity. We hypothesized that autologous MV-infected cells might be a more reliable vehicle than cell-free virions to deliver the infection to tumor cells in subjects with neutralizing titers of anti-measles antibodies. Our in vitro studies, using a dual-color fluorescent model, demonstrated efficient cell-to-cell transfer of infection via heterofusion. In contrast to infection by naked virions, heterofusion between infected cell carriers and tumor cells was more resistant to antibody neutralization. Infected monocytic, endothelial, or stimulated peripheral blood cells could deliver oncolytic MV to tumor lesions in vivo, after intravenous (i.v.) or intraperitoneal (i.p.) administration. Single or repeated i.p. injections of monocytic carriers significantly improved survival of animals bearing human ovarian cancer xenografts. Systemic or i.p. injection of MV-infected cells successfully transferred infection by heterofusion to Raji lymphomas or hepatocellular carcinoma tumors in the presence of neutralizing antibodies. These results suggest a novel strategy for systemic delivery of oncolytic virotherapy in cancer patients that can "bypass" the pre-existing humoral immunity against MV.

UR - http://www.scopus.com/inward/record.url?scp=33846015067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846015067&partnerID=8YFLogxK

U2 - 10.1038/sj.mt.6300020

DO - 10.1038/sj.mt.6300020

M3 - Article

C2 - 17164782

AN - SCOPUS:33846015067

VL - 15

SP - 114

EP - 122

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -